Possibilities of using multidirectional immunomodulators for acute and recurrent infectious and inflammatory diseases of the upper respiratory tract

Author:

Morozova S. V.1ORCID,Selezneva L. V.1ORCID

Affiliation:

1. Sechenov First Moscow State Medical University (Sechenov University)

Abstract

In many countries, with the prevention of acute respiratory diseases in children and adults, the use of various types of biologically active substances of natural and synthetic origin, called immunostimulants of various mechanisms of action, has been introduced. The purpose of this article is to provide a useful overview of main roles of available immunostimulants and their potential for use in inflammatory diseases of the upper respiratory tract. The article discusses aspects of the clinical use of immunomodulatory drugs in acute and recurrent infectious and inflammatory diseases of the respiratory tract (SARS-CoV-2 included). The mechanisms of action of immunomodulators on the immune system are briefly outlined. On the drug Imunorix the evidence base of mechanisms of correction of the immune system in respiratory diseases of the upper respiratory tract is given, as well as the analysis of the clinical efficacy of drug. The use of immunostimulator to increase the level of immunoglobulins (IgA, IgM, IgG) and subpopulations of T-lymphocytes (CD3 +, CD4 +). Also, the use of the drug has shown its usefulness in the appointment of antibacterial drugs in the treatment of upper respiratory tract infectious diseases. This article also provides an overview of recent clinical studies of drug. Researchers from various countries have tried to better clarify and define the mechanisms of action of immunostimulator both in vitro and in vivo. Of course, the improvement in research methodology over the past 20 years, and the acquired knowledge in various areas of clinical immunology, should become the starting point for further research on the drug. Randomized controlled trials of the trial use of the drug in the prevention of acute respiratory infections.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference41 articles.

1. Ferrario B.E., Garuti S., Braido F., Canonica G.W. Pidotimod: the State of Art. Clin Mol Allergy. 2015;13(1):8. doi: 10.1186/s12948-015-0012-1.

2. Caramia G., Clemente E., Solli R., Mei V., Cera R., Carnelli V. et al. Efficacy and Safety of Pidotimod in the Treatment of Recurrent Respiratory Infections in Children. Arzneimittelforschung. 1994;44(12A):1480–1484.

3. Passali D., Calearo C., Conticello S. Pidotimod in the Management of Recurrent Pharyngotonsillar Infections in Childhood. Arzneimittelforschung. 1994;44(12A):1511–1516.

4. Karevold G., Kvestad E., Nafstad P., Kvaerner K.J. Respiratory Infections in Schoolchildren: Co-Morbidity and Risk Factors. Arch Dis Child. 2006;91(5):391–395. doi: 10.1136/adc.2005.083881.

5. Forssell G., Håkansson A., Månsson N.O. Risk Factors for Respiratory Tract Infections in Children Aged 2–5 Years. Scand J Prim Health Care. 2001;19(2):122–125. doi: 10.1080/028134301750235376.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3